# US 6,730,486 B1 · Human βTrCP protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,486 B1
- Document ID: US6730486B1
- Status: Granted
- Kind: B1
- Application number: 09/601,168
- Filed: 2000-07-28
- Granted: 2004-05-04
- Earliest claimed: 1998-01-30
- Assignees: Institut National de la Sante et de la Recherche Medicale; Institut Pasteur
- Inventors: Richard Benarous; Florence Margottin; Hervé Durand; Fernando Arenzana Seisdedos; Mathias Kroll; Jean-Paul Concordet
- Web page: https://patentgrep.com/patent/US6730486B1

## CPC

- C07K 14/47: from mammals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C07K 14/4722: {G-proteins}
- C07K 16/18: against material from animals or humans
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2217/075: inducing loss of function, i.e. knock out
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C12N 2799/021: for the expression of a heterologous nucleic acid
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to the human βTrCP protein for the targeting of proteins towards proteasome degradation pathways, which is capable of interacting with the Vpu protein of HIV-1 virus, with the cell proteins IκB and β-catenin and with the cell protein Skp1p, to its peptide fragments and to the nucleic acid sequences coding for said protein and its fragments. It further relates to the use of the human β-TrCP protein or its peptide fragments for the screening of anti-HIV-1 antiviral agents, antitumoral agents and anti-inflammatory agents, to the antiviral agents, antitumoral agents and anti-inflammatory agents, and to the antibodies directed against said protein and its peptide fragments.

## Claims

### Claim 1

Human βTrCP protein (h-βTrCP) for the targeting of proteins towards proteasome degradation pathways, said protein having SEQ ID NO:2 and being capable of interacting with proteins degradable by proteasome, which possess the phosphorylation unit comprising the amino acids Asp-Ser-Glu-Xaa-Xaa-Ser (SEQ ID NO:9), in which Xaa is any natural amino acid and the serine residues are phosphorylated and said protein comprising the following units having the following positions in the sequence SEQ ID NO:2:
F-box: amino acids 147-191, first WD unit: amino acids 259-292, second WD unit: amino acids 304-332, third WD unit: amino acids 343-373, fourth WD unit: amino acids 387-415, fifth WD unit: amino acids 427-455, sixth WD unit: amino acids 467-492, and seventh WD unit: amino acids 516-544.

### Claim 2 (depends on 1)

Protein according to claim 1, characterized in that it is capable of interacting with the Vpu protein of HIV-1 virus or with the cell proteins Iκβ or β-Catenin.

### Claim 3 (depends on 1)

Protein according to claim 1, characterized in that it is capable of interacting with the Skp1p protein.

### Claim 4 (depends on 1)

A nucleic acid sequence coding for the human protein h-βTrCP according to claim 1, characterized in that it consists of:
a) the DNA sequence of SEQ ID NO:1;
b) a DNA sequence which codes for the human protein h-βTrCP having SEQ ID NO:2; or
c) a mRNA or cDNA sequence corresponding to a) or b).

### Claim 5 (depends on 4)

Expression vector, characterized in that it comprises a nucleic acid sequence according to claim 4 and the means necessary for its expression.

### Claim 6 (depends on 5)

Microorganisms or host cells transformed by an expression vector according to claim 5.

### Claim 7 (depends on 1)

A method of identifying anti-HIV-1 antiviral agents, the method comprising the step of screening anti-HIV antiviral agent candidates using the h-βTrCP protein of claim 1 to determine the capability of the anti-HIV antiviral agent candidates to inhibit the interaction between h-βTrCP protein and Vpu protein, wherein an anti-HIV antiviral agent candidate that inhibits binding between h-βTrCP protein and Vpu protein is identified as an anti-HIV-1 antiviral agent.
